Article info

Download PDFPDF

Assessment of the proposed intellectual property waiver as a mechanism to address the COVID-19 vaccine scarcity problem

Authors

  • Julia Barnes-Weise Global Healthcare Innovation Alliance Accelerator, Durham, North Carolina, USA PubMed articlesGoogle scholar articles
  • Ana Santos Rutschman Institute for Vaccine Science and Policy, Saint Louis University, Saint Louis, Missouri, USA Center for Health Law Studies, Saint Louis University, Saint Louis, Missouri, USA PubMed articlesGoogle scholar articles
  • Reid Adler Capital Technology Law Group, PLLC, Washington, District of Columbia, USA Graduate Program in Biotechnology, Johns Hopkins University, Baltimore, Maryland, USA PubMed articlesGoogle scholar articles
  1. Correspondence to Dr Ana Santos Rutschman, Institute for Vaccine Science and Policy, Saint Louis University, Saint Louis, Missouri, USA; ana.rutschman{at}slu.edu
View Full Text

Citation

Barnes-Weise J, Santos Rutschman A, Adler R
Assessment of the proposed intellectual property waiver as a mechanism to address the COVID-19 vaccine scarcity problem

Publication history

  • First published February 9, 2022.
Online issue publication 
March 10, 2022

Article Versions

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.